Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient

Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemb...

Descripción completa

Detalles Bibliográficos
Autor principal: Colkesen, Yucel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017398/
https://www.ncbi.nlm.nih.gov/pubmed/36937632
http://dx.doi.org/10.1002/ccr3.7116
Descripción
Sumario:Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis.

Ejemplares similares